Vistagen Therapeutics (Nasdaq:VTGN) - Cotización, noticias y análisis

Resumen de acción VTGN

Vistagen Therapeutics, Inc. es una empresa biofarmacéutica que se encuentra en la fase final de su desarrollo clínico y cuyo objetivo principal es transformar el panorama del tratamiento de las personas que padecen ansiedad, depresión y otros trastornos del sistema nervioso central (SNC).

Acerca de la empresa

VTGN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 55.39%

Los analistas coinciden en que el precio de las acciones subirá un 181.9%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene ingresos significativos ($1M)

Competidores de Vistagen Therapeutics, Inc.

Adicet Bio

NasdaqGM:ACET

US$138.0m

Anixa Biosciences

NasdaqCM:ANIX

US$103.0m

Syros Pharmaceuticals

NasdaqGS:SYRS

US$134.7m

Abeona Therapeutics

NasdaqCM:ABEO

US$89.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Vistagen Therapeutics
Historical stock prices
Current Share Price	US$4.77
52 Week High	US$24.71
52 Week Low	US$1.62
Beta	0.81
1 Month Change	-9.66%
3 Month Change	-1.65%
1 Year Change	12.85%
3 Year Change	-94.02%
5 Year Change	-71.25%
Change since IPO	-99.68%

Noticias y actualizaciones recientes

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines

Nov 12

Rentabilidad de los accionistas

	VTGN	US Biotechs	Mercado US
7D	-0.2%	0.1%	2.2%
1Y	12.8%	-1.0%	22.8%

Rentabilidad vs. Industria: VTGN superó al sector US Biotechs , que obtuvo un rendimiento del -2.3% el año pasado.

Rentabilidad vs. Mercado: VTGN obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is VTGN's price volatile compared to industry and market?
VTGN volatility
VTGN Average Weekly Movement	8.9%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: VTGN no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VTGN ha disminuido de 97% a 9% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1998	37	Shawn Singh	www.vistagen.com

Vistagen Therapeutics, Inc. es una empresa biofarmacéutica que se encuentra en las últimas fases clínicas y cuyo objetivo principal es transformar el panorama del tratamiento de las personas que padecen ansiedad, depresión y otros trastornos del sistema nervioso central (SNC). La cartera de productos de la empresa incluye seis candidatos a productos en fase clínica, entre ellos cinco agentes en investigación pertenecientes a fármacos conocidos como ferinas. Su cartera de productos comprende PH94B, un aerosol nasal de fasedienol, que se encuentra en fase III de desarrollo para el tratamiento del trastorno de ansiedad social; y PH10, un aerosol nasal de ituvona que se encuentra en fase II de desarrollo para el tratamiento del trastorno depresivo mayor.

Resumen de fundamentos de Vistagen Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Vistagen Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de VTGN
Capitalización bursátil	US$128.37m
Beneficios(TTM)	-US$32.07m
Ingresos (TTM)	US$1.04m

123.7x

Ratio precio-ventas (PS)

-4.0x

Ratio precio-beneficio (PE)

¿Está VTGN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VTGN
Ingresos	US$1.04m
Coste de los ingresos	US$0
Beneficio bruto	US$1.04m
Otros gastos	US$33.11m
Beneficios	-US$32.07m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.19
Margen bruto	100.00%
Margen de beneficio neto	-3,076.62%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado VTGN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción VTGN

Recompensas

Análisis de riesgos

Competidores de Vistagen Therapeutics, Inc.

NasdaqGM:ACET

US$138.0m

NasdaqCM:ANIX

US$103.0m

NasdaqGS:SYRS

US$134.7m

NasdaqCM:ABEO

US$89.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024

Recent updates

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Vistagen Therapeutics, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer

New major risk - Shareholder dilution

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD)

Vistagen Therapeutics, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Share price stability

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023

Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats

Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain

Vistagen Therapeutics, Inc. Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

VistaGen Therapeutics, Inc. Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

Vistagen Provides Nasdaq Compliance Update

Forecast to breakeven in 2026

VistaGen Therapeutics, Inc. to Report Q3, 2023 Results on Feb 07, 2023

VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) completed the acquisition of Pherin Pharmaceuticals, Inc.

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

VistaGen Therapeutics, Inc. Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Price target decreased to US$2.82

VistaGen Therapeutics, Inc. to Report Q2, 2023 Results on Nov 10, 2022

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

Vistagen Therapeutics, Inc. Announces Completion of an Interim Analysis of PALISADE-2

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Vistagen Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance of Minimum Bid Price

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022

CEO & Director recently bought US$103k worth of stock

Consensus forecasts updated

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$3.36

Vistagen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug Ph94b

VistaGen drops 80% as late-stage study for anxiety therapy fails

Consensus revenue estimates fall by 32%

No longer forecast to breakeven

VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer

VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022

CEO & Director exercised options to buy US$120k worth of stock.

VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder

VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer

Forecast to breakeven in 2025

VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses

Forecast to breakeven in 2025